MICROBIO CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.6 TWD | 0.00% |
|
+0.48% | -17.62% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 5,359 | 5,807 | 26,721 | 31,710 | 31,790 | 28,288 |
| Enterprise Value (EV) 1 | 546.4 | 2,147 | 23,060 | 28,195 | 28,200 | 25,271 |
| P/E ratio | -7.76 x | -24.9 x | 40.5 x | 637 x | 152 x | -23.9 x |
| Yield | - | - | - | 0.06% | 0.06% | - |
| Capitalization / Revenue | 3.7 x | 3.96 x | 16.7 x | 17.8 x | 18.5 x | 17.8 x |
| EV / Revenue | 0.38 x | 1.46 x | 14.4 x | 15.8 x | 16.4 x | 15.9 x |
| EV / EBITDA | -7.48 x | -22.1 x | -22.4 x | -27.3 x | -156 x | -114 x |
| EV / FCF | -2.26 x | -7.2 x | 84.2 x | 86.7 x | 727 x | 1,105 x |
| FCF Yield | -44.3% | -13.9% | 1.19% | 1.15% | 0.14% | 0.09% |
| Price to Book | 0.73 x | 0.85 x | 2.62 x | 2.67 x | 2.63 x | 2.4 x |
| Nbr of stocks (in thousands) | 561,102 | 539,493 | 518,381 | 549,643 | 560,162 | 560,162 |
| Reference price 2 | 9.551 | 10.76 | 51.55 | 57.69 | 56.75 | 50.50 |
| Announcement Date | 4/1/19 | 3/31/20 | 3/10/21 | 3/29/22 | 3/13/23 | 3/7/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1,449 | 1,466 | 1,601 | 1,782 | 1,722 | 1,591 |
| EBITDA 1 | -73.06 | -97.06 | -1,032 | -1,033 | -181.3 | -222.2 |
| EBIT 1 | -132.5 | -161.9 | -1,106 | -1,163 | -279.7 | -320.2 |
| Operating Margin | -9.15% | -11.04% | -69.06% | -65.27% | -16.24% | -20.12% |
| Earnings before Tax (EBT) 1 | -727.6 | -255 | 519.4 | -231.9 | 151.8 | -1,378 |
| Net income 1 | -690.7 | -233.5 | 664.2 | 49.42 | 211.2 | -1,180 |
| Net margin | -47.69% | -15.92% | 41.47% | 2.77% | 12.27% | -74.14% |
| EPS 2 | -1.231 | -0.4321 | 1.273 | 0.0905 | 0.3741 | -2.110 |
| Free Cash Flow 1 | -241.9 | -298.2 | 273.7 | 325.3 | 38.81 | 22.87 |
| FCF margin | -16.7% | -20.34% | 17.09% | 18.26% | 2.25% | 1.44% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | 41.22% | 658.27% | 18.38% | - |
| Dividend per Share | - | - | - | 0.0333 | 0.0365 | - |
| Announcement Date | 4/1/19 | 3/31/20 | 3/10/21 | 3/29/22 | 3/13/23 | 3/7/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 4,813 | 3,660 | 3,661 | 3,515 | 3,590 | 3,018 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -242 | -298 | 274 | 325 | 38.8 | 22.9 |
| ROE (net income / shareholders' equity) | -8.2% | -2.83% | 4.75% | -1.75% | 1.09% | -10% |
| ROA (Net income/ Total Assets) | -0.85% | -1% | -5.77% | -5.02% | -1.16% | -1.34% |
| Assets 1 | 80,902 | 23,411 | -11,520 | -983.9 | -18,189 | 87,919 |
| Book Value Per Share 2 | 13.10 | 12.60 | 19.70 | 21.60 | 21.60 | 21.10 |
| Cash Flow per Share 2 | 4.240 | 2.440 | 1.260 | 1.320 | 2.020 | 1.100 |
| Capex 1 | 168 | 286 | 54.1 | 87.2 | 38.9 | 44.8 |
| Capex / Sales | 11.59% | 19.48% | 3.38% | 4.89% | 2.26% | 2.81% |
| Announcement Date | 4/1/19 | 3/31/20 | 3/10/21 | 3/29/22 | 3/13/23 | 3/7/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -17.62% | 720M | |
| +19.40% | 8.71B | |
| +6.26% | 7.81B | |
| +7.42% | 6.69B | |
| -6.19% | 3.78B | |
| -6.64% | 3.77B | |
| -3.06% | 1.41B | |
| -26.54% | 1.13B | |
| +20.86% | 1.07B | |
| -10.58% | 906M |
- Stock Market
- Equities
- 4128 Stock
- Financials Microbio Co., Ltd.